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Purpose
The relationship between head and neck squamous cell carcinoma (HNSCC) and subtypes
of tropomyosin-related kinase (Trk) has not been studied in-depth. In this study, we evalu-
ated the expression patterns of TrkA, TrkB, and panTrk and their clinicopathological signif-
icance as well as association with p16 expression and human papillomavirus (HPV) status.   
Materials and Methods
Total of 396 radically resected oropharyngeal (n=121) and non-oropharyngeal (n=275) 
HNSCCs were included. Immunohistochemistry for TrkA, TrkB, and panTrk was performed.
In addition, p16 immunohistochemistry was performed to assess the HPV status. Using
HPV-negative HNSCC cell lines, FaDu and CAL27, HPV type 16 E6/E7 gene was transfected,
and then changes of TrkA and TrkB expression were analyzed. 
Results
In the clinical samples of HNSCC, high expression of TrkA and panTrk were more associated
with oropharyngeal and p16 positive squamous cell carcinoma (SCC). In patients with com-
pletely resected (R0-resected) oropharyngeal SCC, high TrkA expression was related to 
superior overall survival and recurrence-free survival (RFS). In patients with R0-resected
oral cavity SCC, high panTrk was related to poor RFS. In HPV type E6/E7 gene-transfected
FaDu and CAL27 cell lines, increase of TrkA expression was observed.  
Conclusion
It seems that expression pattern of panTrk and TrkA differed according to anatomical sites
of HNSCC and was closely related to p16 expression and patient prognosis. Trk expression
should be considered in the context of anatomical site, p16 expression or HPV status and
Trk subtypes.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is a
rare cancer [1]. Recurrence and metastasis occur in about one
third of all HNSCC patients. When recurrence or metastasis
occurs, the outcomes are dismal [2]. Therefore, it is desirable
to have alternative treatment options for such cases. 
Oropharyngeal cancer, in contrast to other non-oropharyn-
geal head and neck cancers, is known to be related to human
papilloma virus (HPV) infection, and patients with HPV-pos-
itive oropharyngeal cancer have a better prognosis than
those with HPV-negative cancer [3]. According to the recent
World Health Organization (WHO) classification [4,5], oro-
pharyngeal squamous cell carcinoma (SCC) is classified as
HPV-positive and HPV-negative oropharyngeal SCC. Regar-
ding ‘HPV-positive’ and ‘HPV-negative,’ the new WHO clas-
sification [4,5] specifically note p16 immunohistochemistry
alone (with appropriate criteria for a positive versus negative
test) as a suitable surrogate marker and recommend the ter-
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minology HPV-positive even if only p16 is performed. Using
moderate to intense nuclear and cytoplasmic p16 immuno-
histochemistry in 70% or more of the tumor cells as surrogate
marker for HPV status has been widely validated, especially
in oropharyngeal SCC [6,7]. HPV status appears to affect
tumor characteristics in patients with oropharyngeal cancer,
but the underlying mechanism has not yet been clarified.
Trophomyosin-related kinases (Trk), namely TrkA, TrkB,
and TrkC, belong to a family of neurotrophin receptor tyro-
sine kinases and are encoded by the NTRK1, NTRK2, and
NTRK3 genes, respectively. TrkA, TrkB, and TrkC bind to
nerve growth factor, brain-derived neurotrophic factor, and
neurotrophin 3, respectively [8]. In HNSCC, TrkB is known
to be overexpressed and related to oncogenesis, tumor pro-
gression, and conventional chemotherapy resistance [9,10].
While attempts to describe Trk expression patterns have
drawn increasing interest, Trk expression status has rarely
been studied in clinical samples of HNSCC. In this study, we
sought to evaluate the expression status of Trk in oropharyn-
geal cancer and non-oropharyngeal cancer and to determine
its clinicopathological significance. In addition, possible asso-
ciations between HPV status, p16 expression and Trk protein
expression were investigated.
Materials and Methods
1. Patients, samples, and clinical data 
Formalin-fixed, paraffin-embedded (FFPE) specimens
were obtained from consecutive HNSCC patients who under-
went surgical resection with curative aim at Severance Hos-
pital, Seoul, Korea, between 2005 and 2012. Appropriate
cases were selected from among the archived cases. Inclusion
criteria were as follows: available tumor tissue, relevant clin-
ical data regarding smoking status and survival data, absence
of preoperative treatment, and no clinicopathologic evidence
of distant metastasis at the time of surgery. We excluded
HNSCC tissue samples that had been subjected to decalcifi-
cation for accurate immunohistochemistry. Ultimately, 121
oropharyngeal cases and 275 non-oropharyngeal cases, total
396 cases were selected, among which complete R0 resection,
Fig. 1.  Expression pattern of Trk protein and p16 using immunohistochemistry (!200). Representative expression as assessed
by Trk immunohistochemistry: Trk showed diffuse cytoplasmic staining in tumor cells. The four cases shown had different
intensities of Trk expression in all tumor cells. (A) Negative, H-score 0. (B) Intensity 1, H-score 100. (C) Intensity 2, H-score
200. (D) Intensity 3, H-score 300. Strong and diffuse nuclear and cytoplasmic staining of p16 immunohistochemical staining
(E) and negative staining was observed (F). 
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defined histologically as tumor-free resection margins,
achieved in 305 (S1 Table). Several pathologic factors, includ-
ing tumor size, lymphovascular invasion, perineural inva-
sion, pathologic TNM staging, according to the 7th American
Joint Committee on Cancer (AJCC) criteria and tumor clas-
sification by the WHO system [11,12], were obtained from
the slide review by two individual pathologists (Y.A. Cho
and S.O. Yoon). Clinical data and survival outcomes were
collected and reviewed from patients’ medical records. The
median follow-up period was 37.1 months (range, 0.8 to 99.6
months). Other clinicopathologic characteristics are descri-
bed in S1 Table. 
2. Tissue microarray preparation 
Sections of FFPE tissues were prepared and stained with
hematoxylin and eosin. Representative tumor areas were
confirmed microscopically, selected two or three different
representative areas per case, and used for tissue microarray
(TMA) construction as previously described [13].
3. Immunohistochemistry and interpretation
Immunohistochemistry was performed on 4-µm TMA tis-
sue sections with a Ventana Bench Mark XT Autostainer
(Ventana Medical Systems, Tucson, AZ) as described in pre-
vious reports [14,15]. The following primary antibodies were
tested: anti-TrkA antibody (1:100 dilution, EP1058Y, rabbit
monoclonal antibody, Abcam, Cambridge, MA), anti-TrkB
antibody (1:300 dilution, ab18987, rabbit polyclonal antibody,
Abcam), anti-panTrk (1:100 dilution, Trk A+B+C, EPR17341,
rabbit monoclonal antibody, Abcam), and p16 (E03347, mouse
monoclonal antibody, RTU, Ventana Medical Systems). 
Expression of Trk subtypes was analyzed according to the
semi-quantitative H-score method; this method yields a total
score range of 0-300 as previously described [16]. The inten-
sity of expression was scored by cytoplasmic staining only
(Fig. 1A-D). Conventionally accepted criteria were used for
p16 immunohistochemistry as previously described. Positive
and negative pattern is described in Fig. 1E and F respec-
tively [17-22].
4. Cell lines and culture
HNSCC cell lines FaDu, a cell line derived from HPV-neg-
ative pharynx SCC, and CAL27, a cell line derived from
HPV-negative tongue SCC were prepared. FaDu cell line was
maintained in RPMI-1640 medium (22400-089, Gibco, Life
Technologies, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS; 5000-044, Gibco, Life Technologies).
CAL27 and UMSCC 47 cell lines were maintained in Dul-
becco's modified Eagle's medium (SH30243.01, HyClone,
Thermo Scientific, Logan, UT) supplemented with 10% FBS
(6000-044, Gibco, Life Technologies).
5. Transfection with HPV gene
Plasmid p1321 HPV-16 E6/E7 or empty plasmid vector
(Addgene, Cambridge, MA) was transfected into each cell-
line of FaDu and CAL27 by using TransIT-X2 Dynamic 
Delivery System (Mirus, Madison, WI). 
6. RNA isolation and real-time polymerase chain reaction 
RNA was isolated after 24 hours and 48 hours of transfec-
tion using RNeasy plus mini kit (Qiagen, Valencia, CA).
cDNA was made using qPCRBIO cDNA synthesis kit (PCR
Biosystems, London, UK). Primers of GAPDH, E6, E7, TrkA,
TrkB, and TrkC were manufactured (Integrated DNA Tech-
nologies, Skokie, IL), and primer sequences were summa-
rized in S2 Table. Quantitative polymerase chain reaction
(PCR) was performed using 2! qPCRBIO SyGreen Mix 
Lo-Rox (PCR Biosystems) as PCR reagent and ABI 7500 Real-
Time PCR System (Applied Biosystems, Thermo Fisher Sci-
entific) with the following cycling parameters: 95°C for 2
minutes, 40 cycles of 95°C for 5 seconds and 60°C for 30 sec-
onds, 95°C for 15 seconds, and 60°C for 10 minutes. Relative
mRNA expression levels were determined by the compara-
tive method (2-ddCt). 
7. Statistical analysis
Statistical analyses were conducted using IBM SPSS ver.
22 software for Windows (IBM Corp., Armonk, NY). The
Mann-Whitney U test, Kruskal-Wallis test and chi-square
test, were used to analyze the significance of differences 
between the evaluated variables. Overall survival (OS) was
measured from the date of initial diagnosis to that of death
or the last follow-up visit. Recurrence-free survival (RFS) was
measured from the date of initial diagnosis to that of disease
progression, defined as cancer recurrence, continuance of sta-
ble disease/partial remission/progressive disease without
complete remission, or cancer-related death during the study
period. The Kaplan-Meier method was used to analyze sur-
vival rates, and differences were compared using the log-
rank test. Multivariate regression analysis was performed
using a Cox proportional hazards model. Two-sided p-val-
ues < 0.05 were considered statistically significant. 
8. Ethical statement
This study was approved by the Institutional Review
Board of Severance Hospital with a waiver of informed con-
sent (No. 4-2015-0954).
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Fig. 2.  Expression of Trk protein in head and neck squamous cell carcinomas according to anatomical location and p16
status. (A) H-scores of TrkA and panTrk were significantly higher at oropharyngeal sites than non-oropharyngeal areas 
(p < 0.001). However, there was no significant difference in H-scores of TrkB according to anatomical site. (B) H-scores of
TrkA and panTrk were higher in p16 positive cases than p16 negative cases. No significant difference was observed in the
H-score of TrkB between p16 positive cases and p16 negative cases.
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Fig. 3.  Alteration of TrkA and TrkB expression and proliferation ability by HPV-16 oncogene. (A) Increased level of TrkA
mRNA 48 hours after transfection in FaDu cell line. (B) Increased level of TrkA mRNA 48 hours after transfection in CAL-
27 cell-line. (C) Slight decreased level of TrkB mRNA in FaDu cell line. (D) Decreased level of TrkB in CAL27 cell line. 
Increased level of TrkC mRNA 48 hours after transfection in FaDu cell line (E) and CAL27 cell line (F). CTR, transfection
with empty vector; HPV, transfection with HPV-16 oncogene.
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Results
1. Expression status of Trk protein according to anatomical
site and p16 expression
In overall HNSCC cases, TrkA expression was on average
91.8 (range, 0 to 230), TrkB 36.8 (range, 0 to 278), and panTrk
79.2 (range, 0 to 263) among all HNSCC cases (S3 Fig.). Trk
expression varied among anatomical sites. Expression of
TrkA and panTrk was significantly higher in oropharyngeal
SCCs than non-oropharyngeal SCCs. Also both expressions
were significantly higher in p16 positive HNSCCs than neg-
ative cases. However, TrkB expression showed no correlation
with anatomical sites and p16 status (Fig. 2A and B, S4 and
S5 Figs.).
Variable No.
TrkA expression panTrk expression
(n=391)a) High (n=160) Low (n=231)
p-value
High (n=169) Low (n=222)
p-value
Age (yr)
< 58 190 76 (47.5) 114 (49.4) 0.758 73 (43.2) 117 (52.7) 0.067
! 58 201 84 (52.5) 117 (50.6) 96 (56.8) 105 (47.3)
Sex
Female 97 40 (25.0) 57 (24.7) > 0.999 34 (20.1) 63 (28.4) 0.076
Male 294 120 (75.0) 175 (75.3) 135 (79.9) 159 (71.6)
Location
Hypopharynx 28 8 (5.0) 20 (8.7) 0.011 13 (7.7) 15 (6.8) < 0.001
Larynx 42 12 (7.5) 30 (13.0) 16 (9.5) 26 (11.7)
Oral cavity 200 77 (48.1) 123 (53.2) 57 (33.7) 143 (64.4)
Oropharynx 121 63 (39.4) 58 (25.1) 83 (49.1) 38 (17.1)
Smoking
Non-smoker 151 70 (43.8) 81 (35.1) 0.214 55 (32.5) 96 (43.2) 0.085
Ex-smoker 80 29 (18.1) 51 (22.1) 40 (23.7) 40 (18.0)
Smoker 160 61 (38.1) 99 (42.9) 74 (43.8) 86 (38.7)
p16 IHC status
Negative 269 88 (55.0) 181 (78.4) < 0.001 86 (50.9) 183 (82.4) < 0.001
Positive 122 72 (45.0) 50 (21.6) 83 (49.1) 39 (17.6)
Lymphovascular invasion
Absent 315 118 (73.8) 197 (85.3) 0.004 119 (70.4) 196 (88.3) < 0.001
Present 76 42 (26.3) 34 (14.7) 50 (29.6) 26 (11.7)
Perineural invasion
Absent 337 132 (82.5) 205 (88.7) 0.054 139 (82.2) 198 (89.2) 0.055
Present 54 28 (17.5) 26 (11.3) 30 (17.8) 24 (10.8)
Pathologic T category
pT1-2 321 128 (80.0) 193 (83.5) 0.421 133 (78.7) 188 (84.7) 0.143
pT3-4 70 32 (20.0) 38 (16.5) 36 (21.3) 34 (15.3)
Lymph node metastasis
Absent 172 62 (38.8) 110 (47.6) 0.097 53 (31.4) 119 (53.6) < 0.001
Present 219 98 (61.3) 121 (52.4) 116 (68.6) 103 (46.4)
Perinodal soft tissue extensionb)
Absent 52 25 (34.7) 27 (35.1) > 0.999 24 (29.6) 28 (41.2) 0.169
Present 97 47 (65.3) 50 (64.9) 57 (70.4) 40 (58.8)
Table 1. Clinicopathological characteristics of 391 HNSCCs according to TrkA and panTrk expression status
Values are presented as number (%). HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry. a)TrkA
and PanTrk immunohistochemistry was performed in all 396 cases but five cases could not be interpreted because of a dam-
aged core, b)The perinodal soft tissue extension status was evaluated in 149 HNSCC cases.
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2. Alteration of Trk protein expression by HPV gene trans-
fection 
After transfection of HPV-16 E6/E7 gene inserted plasmid,
significant increase of E6 and E7 gene expression was con-
firmed at the time of 24 and 48 hours after transfection (S6 Fig.).
The levels of TrkA, TrkB and TrkC mRNA level were meas-
ured 48 hours after transfection; and both FaDu and CAL27
transfected with HPV-16 E6/E7 genes revealed increased 
expression of TrkA and TrkC when compared to control 
(Fig. 3A, B, E and F). TrkB gene expression showed a ten-
dency of decreased expression after HPV-16 E6/E7 gene
transfection (Fig. 3C and D). 
3. Clinicopathological characteristics in conjunction with
Trk expression
Among all HNSCC cases, high TrkA and panTrk expres-
sion was significantly associated with the presence of lym-
phovascular invasion and p16 expression (Table 1). In addi-
tion, high panTrk expression was significantly associated
with the presence of lymph node metastasis (p < 0.001).
However, other clinicopathologic variables were not related
to the expression of TrkA and panTrk proteins (Table 1). In
oropharyngeal HNSCCs, only p16 expression was signifi-
cantly associated with TrkA and panTrk protein expression
(p < 0.001 and p=0.038, respectively) (Table 2). However,
panTrk expression was significantly correlated with the pres-
ence of lymphovascular invasion (p < 0.001), presence of per-
ineural invasion (p=0.007), advanced pathologic T category
Variable No.
TrkA expression panTrk expression
(n=121) High (n=63) Low (n=58)
p-value
High (n=83) Low (n=38)
p-value
Age (yr)
< 58 57 27 (42.9) 30 (51.7) 0.365 38 (45.8) 19 (50.0) 0.698
 58 64 36 (57.1) 28 (48.3) 45 (54.2) 19 (50.0)
Sex
Female 20 8 (12.7) 12 (20.7) 0.328 14 (16.9) 6 (15.8) > 0.999
Male 101 55 (87.3) 46 (79.3) 69 (83.1) 32 (84.2)
Smoking
Non-smoker 38 22 (34.9) 16 (27.6) 0.676 26 (31.3) 12 (31.6) 0.345
Ex-smoker 25 12 (19.0) 13 (22.4) 20 (24.1) 5 (13.2)
Smoker 58 29 (46.0) 29 (50.0) 37 (44.6) 21 (55.2)
p16 IHC status
Negative 29 6 (9.5) 23 (39.7) < 0.001 15 (18.1) 14 (36.8) 0.038
Positive 92 57 (90.5) 35 (60.3) 68 (81.9) 24 (63.2)
Lymphovascular invasion
Absent 81 39 (61.9) 42 (72.4) 0.250 54 (65.1) 27 (71.1) 0.541    
Present 40 24 (38.1) 16 (27.6) 29 (34.9) 11 (28.9)
Perineural invasion
Absent 111 56 (88.9) 55 (94.8) 0.327 75 (90.4) 36 (94.7) 0.503
Present 10 7 (11.1) 3 (5.2) 8 (9.6) 2 (5.3)
Pathologic T category
pT1-2 101 50 (79.4) 51 (87.9) 0.230 69 (83.1) 32 (84.2) > 0.999
pT3-4 20 13 (20.6) 7 (12.1) 14 (16.9) 6 (15.8)
Lymph node metastasis
Absent 23 12 (19.0) 11 (19.0) > 0.999 18 (21.7) 5 (13.2) 0.325
Present 98 51 (81.0) 47 (81.0) 65 (78.3) 33 (86.8)
Perinodal soft tissue extensiona)
Absent 22 13 (32.5) 9 (31.0) > 0.999 13 (27.7) 9 (40.9) 0.284
Present 47 27 (67.5) 20 (69.0) 34 (72.3) 13 (59.1)
Table 2. Clinicopathological characteristics of 121 oropharyngeal HNSCCs according to TrkA and panTrk expression status
Values are presented as number (%). HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry. a)The
perinodal soft tissue extension status was evaluated in 69 oropharyngeal HNSCC cases.
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(p=0.045), and presence of lymph node metastasis (p=0.002)
in non-oropharyngeal HNSCC (Table 3). Both TrkA and
panTrk expression showed no significant correlation with
perinodal soft tissue extension status. TrkB expression status
showed no statistically significant correlation with any of the
clinico-pathologic factors (S7 Table).
4. Prognostic impact of Trk protein expression on HNSCC
patients
Among R0 resected HNSCCs (n=305), five cases were not
available for Kaplan-Meier analysis due to the absence of fol-
low-up data. Among 300 cases of R0 resected HNSCCs, high
TrkA expression showed a tendency to be related to superior
OS (Fig. 4A), although it was not associated with RFS 
(Fig. 4B). Especially in R0-resected oropharyngeal SCCs
(n=82), high TrkA expression was significantly related to 
superior OS (Fig. 4C) and RFS (Fig. 4D). In non-oropharyn-
geal SCCs, especially in those of oral cavity (n=181), high
panTrk expression tended to be related to poor OS and infe-
rior RFS than those with low panTrk expression (Fig. 4E and
F). TrkB expression was not related to OS or RFS in oropha-
ryngeal or non-oropharyngeal SCCs (S8 Fig.). Other non-
oropharyngeal SCCs showed no significant correlation with
the expression of TrkA and panTRK protein in Kaplan-Meier
analysis (S9 and S10 Figs.).
In multivariate Cox analysis in R0 resected oropharyngeal
HNSCC, only p16 expression status and pathologic T cate-
gory acts as independent prognostic factors for OS and RFS
(Table 4). However, in R0 resected oral cavity HNSCCs, age,
Variable
No.                      TrkA expression panTrk expression
(n=270)a) High (n=97) Low (n=173)
p-value
High (n=86) Low (n=184)
p-value
Age (yr)
< 58 133 49 (50.5) 84 (48.6) 0.800 35 (40.7) 98 (53.3) 0.067
! 58 137 48 (49.5) 89 (51.4) 51 (59.3) 86 (46.7)
Sex
Female 77 32 (33.0) 45 (26.0) 0.261 20 (23.3) 57 (31.0) 0.247
Male 193 65 (67.0) 128 (74.0) 66 (76.7) 127 (69.0)
Smoking
Non-smoker 113 48 (49.5) 65 (37.6) 0.163 29 (33.7) 84 (45.7) 0.180
Ex-smoker 55 17 (17.5) 38 (22.0) 20 (23.3) 35 (19.0)
Smoker 102 32 (33.0) 70 (40.5) 37 (43.0) 65 (35.3)
p16 IHC status
Negative 240 82 (84.5) 158 (91.3) 0.107 71 (82.6) 169 (91.8) 0.036
Positive 30 15 (15.5) 15 (8.7) 15 (17.4) 15 (8.2)
Lymphovascular invasion
Absent 234 79 (81.4) 155 (89.6) 0.064 65 (75.6) 169 (91.8) < 0.001
Present 36 18 (18.6) 18 (10.4) 21 (24.4) 15 (8.2)
Perineural invasion
Absent 226 76 (78.4) 150 (86.7) 0.087 64 (74.4) 162 (88.0) 0.007
Present 44 21 (21.6) 23 (13.3) 22 (25.6) 22 (12.0)
Pathologic T category
pT1-2 220 78 (80.4) 142 (82.1) 0.746 64 (74.4) 156 (84.8) 0.045
pT3-4 50 19 (19.6) 31 (17.9) 22 (25.6) 28 (15.2)
Lymph node metastasis
Absent 149 50 (51.5) 99 (57.2) > 0.999 35 (40.7) 114 (62.0) 0.002
Present 121 47 (48.5) 74 (42.8) 51 (59.3) 70 (38.0)
Perinodal soft tissue  extensionb)
Absent 30 12 (37.5) 18 (37.5) > 0.999 11 (32.4) 19 (41.3) 0.487
Present 50 20 (62.5) 30 (62.5) 23 (67.6) 27 (58.7)
Table 3. Clinicopathological characteristics of 270 non-oropharyngeal HNSCCs according to Trk expression status
Values are presented as number (%). HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry. a)Trk
immunohistochemistry was performed in all 275 cases but five cases could not be interpreted because of a damaged core,
b)The perinodal soft tissue extension status was evaluated in 80 non-oropharyngeal HNSCC cases.
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Fig. 4.  Kaplan-Meier analysis of R0-resected head and neck squamous cell carcinomas (SCCs) in aspect of anatomical sites.
(A) In the analysis of 300 R0 resected cases, TrkA high expression group tended to have a longer overall survival (OS) than
the Trk low expression group (p=0.060). (B) No significant difference was observed in recurrence-free survival (RFS) accord-
ing to TrkA expression status (p=0.348). (C) In the analysis of 82 R0 resected oropharyngeal SCCs, TrkA high group had a
significantly longer OS than the TrkA low expression group (p=0.044). (D) In addition, the TrkA high group showed longer
RFS than the TrkA low expression group (p=0.032). (E) In 180 R0 resected oral cavity SCCs, high panTrk expression tended
to be related to poor OS (p=0.065). (F) Furthermore, the high panTrk group showed a significantly inferior RFS than the low
panTrk group (p=0.001).
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OS RFS
Variable Univariate Multivariate Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age (yr)a)
< 58 1 ( - 1 ( -
! 58 0.414 (0.076-2.264) 0.309 - - 0.978 (0.297-3.217) 0.970 - -
Sex
Female 1 ( - 1 ( -
Male 3.291 (0.097-112.2) 0.508 - - 3.395 (0.285-48.89) 0.333 - -
Smoking
Non-smoker 1 - 1 ( -
Ex-smoker 2.220 (0.070-70.69) 0.652 - - 1.526 (0.081-28.82) 0.778 - -
Smoker 6.063 (0.369-99.61) 0.207 - - 8.095 (0.934-70.13) 0.058 - -
p16 IHC 
status
Negative 1 ( 1 ( 1 ( 1 (
Positive 0.135 (0.022-0.828) 0.030 0.192 (0.034-1.092) 0.063 0.281 (0.084-0.939) 0.039 0.281 (0.083-0.953) 0.042
Lymphovascular 
invasion 
Absent 1 ( - 1 ( -
Present 0.486 (0.057-4.158) 0.510 - - 1.476 (0.431-5.058) 0.536 - -
Perineural 
invasion 
Absent 1 ( - 1 ( -
Present 0.346 (0.001-101.0) 0.714 - - 0.345 (0.005-22.01) 0.616 - -
Pathologic 
T category
pT1-2 1 ( 1 ( 1 ( 1 (
pT3-4 11.65 (2.327-58.34) 0.003 11.305 (2.173-58.803) 0.004 7.038 (2.048-24.19) 0.002 7.041 (2.023-24.51) 0.002
Lymph node 
metastasis
Absent 1 ( - 1 ( -
Present 1.592 (0.185-13.723) 0.657 - - 1.322 (0.285-6.132) 0.713 - -
TrkA 
expression
Low 1 ( - 1 ( -
High 0.021 (0.000-18.39) 0.265 - - 0.144 (0.018-1.126) 0.065 - -
TrkB 
expression
Low 1 ( - 1 ( -
High 0.838 (0.152-4.630) 0.839 - - 0.655 (0.173-2.478) 0.533 - -
PanTrk 
expression
Low 1 ( - 1 ( -
High 0.416 (0.084-2.060) 0.282 - - 0.466 (0.142-1.531) 0.208 - -
Table 4. Univariate and multivariate analysis of RFS and OS in R0 resected oropharyngeal HNSCC (n=82)
RFS, recurrence-free survival; OS, overall survival; HNSCC, head and neck squamous cell carcinoma; HR, hazard ratio; CI,
confidence interval; IHC, immunohistochemistry. a)Median age of 82 patients was 58.0 years.
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presence of lymphovascular invasion and advanced patho-
logic T category were independent factors for OS and RFS
(S11 Table). Higher panTrk expression tends to relate with
inferior RFS in multivariate analysis (p=0.060) (S11 Table). In
Kaplan-Meier analysis of 91 R1-resected head and neck squa-
mous cell carcinomas in association with Trk expression, no
significant difference was observed in OS and RFS according
to TrkA, panTRkA, or TrkB expression (S12 Fig.).
Discussion
In this study, we evaluated and compared the expression
status of subtypes of Trk in oropharyngeal cancer and non-
oropharyngeal cancer and investigated the relationship 
between the expression levels of these subtypes and p16 
expression status, clinicopathological variables, and patient
prognosis. 
In our study, cytoplasmic staining of tumors varied in 
intensity. Recent studies have described the reliability of pan-
Trk and TrkA immunohistochemical staining in the predic-
tion of NTRK gene alteration [23-25]: one study reported 15
cases of positive pan-Trk positive staining in 16 cases of
known NTRK fusions. Interestingly, cytoplasmic staining 
accompanied by other expression patterns has been found to
be associated with specific NTRK fusion patterns: EML4-
NTRK3 fusion with nuclear staining, LMNA-NTK1 fusion
with nuclear membrane staining, and TPM3/4-NTRK1/3
and TRAF2-NTRK2 fusion with membranous staining [24].
Also, research suggest that strong cytoplasmic TrkA expres-
sion might be related with NTRK1 gene fusion in colorectal
cancers [23] and might be indicative of gene copy number
gain in solid tumors, such as lung adenocarcinoma, and
colon and bile duct cancer [25].
We observed that TrkA and panTrk were expressed more
highly in oropharyngeal than non-oropharyngeal SCCs.
Oropharyngeal cancer shows a significant association with
HPV infection, in contrast to non-oropharyngeal SCC. Car-
cinomas driven by HPV infection induce p16 protein over-
expression through loss of control over cell cycle regulation;
therefore, p16 immunohistochemistry is a reliable surrogate
marker for HPV infection [18,19,21,22,26,27]. These previous
findings and those of the present study suggest that high 
expression of TrkA and panTrk might be related to HPV-dri-
ven molecular changes during the carcinogenesis of oropha-
ryngeal SCCs. In the present study, HPV gene transfection
on the originally HPV-negative HNSCC cell-lines altered
TrkA and TrkB gene expression. Especially, the increment of
TrkA and TrkC gene expression after HPV gene transfection
reflects our observation about the close correlation between
high TrkA and panTrk (A+B+C) expression and p16 positive
HNSCC cases. From the findings, HPV infection may play a
role in regulation of TrkA and TrkC expression. Further 
in-depth studies are needed for the detailed mechanisms 
related to the interaction between HPV infection and each
Trk subtype regulation. 
Besides HPV infection, genetic alteration may be related to
alter Trk expression. According to recent The Cancer Genome
Atlas data for HNSCCs (530 samples/528 patients; www.
cbioportal.org/study?id=hnsc_tcga#summary); however,
mutations of the NTRK1, 2, and 3 genes have a very low fre-
quency (0.6%, 0.6%, and 2.1%, respectively), and copy num-
ber alterations (amplifications or deletions) are also low
frequency (1.2%, 0.8%, and 0.6%, respectively). These find-
ings suggest that genetic mutations or copy number alter-
ations are not the major factors underlying TrkA and panTrk
overexpression in HNSCCs. A recent study of colorectal ade-
nocarcinomas reported that high TrkA protein expression
was related to NTRK1 gene rearrangement [28]. Although
colorectal adenocarcinomas are very different from HNSCCs
in terms of anatomical origin, histology, and biology of car-
cinogenesis, investigation of NTRK gene rearrangements
should be performed to gain insights into the mechanism un-
derlying TrkA and panTrk overexpression in HNSCCs. 
In the present study, high TrkA expression was related to
favorable prognosis. Given that HPV-positive oropharyngeal
SCCs have a more favorable prognosis than HPV-negative
carcinomas [29], and that high TrkA expression was associ-
ated with p16 positivity in the present study, close associa-
tion between high TrkA expression and the favorable out-
come of oropharyngeal SCCs may be related to HPV infec-
tion. Further in-depth study, however, may be necessary
about the relations among HPV infection, Trk regulation,
tumor cell growth. 
In contrast, high panTrk expression was related to poor
outcomes in patients with oral cavity SCCs, but couldn’t
prove as independent prognostic factor for OS and RFS. 
Regarding previous studies about pancreatic cancer and ade-
noid cystic carcinoma [30,31], overexpression of Trk protein
is associated with tumor metastasis or perineural invasion
which is concordant with our result. Given that panTrk 
includes TrkA, B, and C, among TrkA, B, and C or the com-
bination of these Trk subtypes affects lymphovascular inva-
sion and perineural invasion and contribute to the poor
outcome in patients with oral cavity SCCs. However, we
were not able to assess TrkC protein expression by immuno-
histochemistry, because of the lack of commercially available
and reliable antibodies. Although further studies are requi-
red to identify the prognostic relevance of TrkC, oral cavity
SCCs showing high panTrk expression may be candidates
for treatment with panTrk inhibitors. 
In previous in vitro study, TrkB expression may be related
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with tumor proliferation and chemotherapy resistance [32-34].
However, we could not prove the relationship between TrkB
expression and OS or RFS. This might be limitation of 
immunohistochemical staining of TrkB protein. Since our
study cohort is composed of surgically resected specimen
without prior therapy, there may be need for TrkB expres-
sion status in samples of recurrent HNSCC or chemother-
apy-resistant cases. 
Trk protein expression seems to differ according to ana-
tomical site and p16 expression or HPV status with clinical
relevance. As a result, Trk expression status should be con-
sidered in the context of anatomical site and Trk subtype
when considering treatment using Trk inhibitors.
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